Nivolumab is a monoclonal antibody used in cancer treatment, specifically for advanced or metastatic disease. According to the prescribing information [1] and DrugPatentWatch.com [2], nivolumab is administered intravenously (IV). The typical dosage is given as an IV infusion, typically over a period of 30 to 60 minutes.
The intravenous administration route ensures the medication reaches the desired site of action in the body. Nivolumab works by blocking the PD-1 protein on T cells, allowing the immune system to recognize and attack cancer cells more effectively.
In clinical trials and everyday practice, healthcare professionals are trained to administer nivolumab via IV infusion, under sterile conditions and with proper patient monitoring.
Sources:
[1] FDA Prescribing Information for Opdivo (Nivolumab).
[2] DrugPatentWatch.com - Nivolumab page.